Molecular glue degrader reduces systemic inflammation
Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.
“These remarkable interim data from our ongoing Phase I study of MRT-8102 demonstrate for the first time that treatment with an oral molecular glue degrader of NEK7 led to levels of CRP reduction comparable to those previously reported with biologic therapies,” said Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics. “We believe our data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NLRP3/IL-1/IL-6 pathway and establish the significant potential opportunity for MRT-8102 in multiple chronic inflammatory diseases, including ASCVD.”
Summary of key interim study results:
- Rapid, deep and sustained degradation of NEK7 was observed in peripheral blood T cells (~80 to 90%) in the SAD, MAD, and Part 3 cohorts across all dose levels.
- MRT-8102 led to significant reductions in serum hsCRP across all dose levels following single dose drug administration and seven-day multiple dose drug administration.
- In the MAD cohorts, MRT-8102 led to marked suppression of IL-1β secretion in patients with elevated CRP levels at baseline.
- When analysing high CRP subjects across all dose levels, significant reductions of endogenous IL-6 were observed, with median IL-6 levels dropping by 55%, to levels below the cardiovascular risk threshold.
- In two subjects with elevated basal levels of cerebrospinal fluid (CSF) IL-6, a significant decrease of 75% in CSF IL-6 was noted; plasma IL-6 levels at baseline for these two subjects was low, potentially suggesting central nervous system /CSF-specific effects of MRT-8102.
- In Part 3 of the study in subjects with elevated CVD risk, in 24 subjects dosed for four weeks, MRT-8102 resulted in a decrease of hsCRP of 85% after four weeks of dosing, compared with no significant change in hsCRP for the placebo group. In addition, 94% of subjects showed suppression of hsCRP to <2mg/L after four weeks of dosing (median baseline level was 6.3mg/L).
- The MRT-8102 safety profile observed to date was favourable. AEs were limited in number, mild to moderate, and self-resolving.
Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, commented: “Based on the highly encouraging data for MRT-8102 we have observed so far, we are expanding our proof-of-concept GFORCE-1 study in subjects with elevated CVD risk, in order to accelerate the anticipated Phase II (GFORCE-2) study of MRT-8102 in ASCVD. Moreover, we are evaluating additional Phase II proof-of-concept studies in metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis, conditions strongly linked to NLRP3 pathway activation.”
Diana Turner, Deputy Editor, DDW
